sb 202190 has been researched along with Hypertension in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Touyz, RM | 1 |
| He, G | 1 |
| El Mabrouk, M | 1 |
| Diep, Q | 1 |
| Mardigyan, V | 1 |
| Schiffrin, EL | 1 |
1 other study available for sb 202190 and Hypertension
| Article | Year |
|---|---|
Differential activation of extracellular signal-regulated protein kinase 1/2 and p38 mitogen activated-protein kinase by AT1 receptors in vascular smooth muscle cells from Wistar-Kyoto rats and spontaneously hypertensive rats.
Topics: Angiotensin II; Animals; Enzyme Activation; Enzyme Inhibitors; Flavonoids; Hypertension; Imidazoles; | 2001 |